Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Not Yet Recruiting NCT05758480

Characterization of the Immunometabolic Signature in Long COVID-19.

Conditions: Long COVID

Sex: All
Ages: 18 Years – N/A
Healthy volunteers: 1
Phase: NA
Enrollment: 100
Sponsor: University Hospital, Angers

Location: France

Summary

The primary objective of this study is to identify immunometabolic signatures associated with Long COVID in plasma and peripheral blood mononuclear cells (PBMC).

Eligibility Criteria

A/ Inclusion Criteria:For all patients:Age > 18 yearsSymptomatic COVID-19 diagnosed after 01JAN2021, confirmed by RT-PCR or Antigen testLast SARS-CoV-2 infection diagnosed more than 12 weeks before inclusionPatient covered by the French health insuranceSignature of the informed consentFor patient with Long COVID :At least one of the following symptoms during the week preceding inclusion: abnormal fatigue, dyspnoea sine materia, abnormal pain (chest, joint, muscle, headache), unusual neurocognitive disorders (concentration disorders, "brain fog", language/memory disorders, paraesthesia)Absence of Return to Usual Health after SARS-CoV-2 infection (patient declaration)Absence of alternative diagnosis for the symptomsFor COVID-19 recovered patient (Control) :None of the following symptoms in the 3 week before inclusion: abnormal fatigue, dyspnoea sine materia, abnormal pain (chest, joint, muscle, headache), unusual neurocognitive disorders (concentration disorders, "brain fog", language/memory disorders, paraesthesia)Return to Usual Health after SARS-CoV-2 infection (patient declaration)B/ Exclusion Criteria:History of severe COVID-19 (Hospitalization)Symptoms caused by sequelae of SARS-CoV-2 infection (in particular, persistence of lung parenchymal abnormalities : pulmonary fibrosis, persistent alveolitis on CT-Scan)Significant Depression or anxiety symptoms, as assessed by a > 10 score on the A or D items of the Hospital anxiety and depression scale (HAD)Presence of one of the following diseases:Inborn errors of metabolismestimated Glomerular filtration rate < 30 ml/min (MDRD)Autoimmune diseaseImmunosuppressive treatment or immune deficiencySymptomatic heart failureRespiratory failure (COPD stage ≥ 3 or oxygen therapy)Solid cancer or active blood diseaseSevere malnutrition (albumin < 30 g/L or weight loss ≥10% in 6 months)Obesity with BMI ≥ 35 kg/m²Diabetes not controlled by diet alonePregnant, breastfeeding or parturient womenDeprivation of liberty by judicial or administrative decisionMandatory Psychiatric CareProtected by decision of lawUnable to express consent

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05758480). StuddyBuddy aggregates publicly available trial information.